© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Olaparib stands out as a targeted cancer therapy widely used for certain types of breast, ovarian, pancreatic, and prostate cancers. By functioning as a poly(ADP-ribose) polymerase (PARP) inhibitor, Olaparib helps prevent cancer cells from repairing their DNA, making them more vulnerable to treatment. The growing popularity of precision medicine owes a lot to compounds like Olaparib, which enhance patient outcomes and open doors for those with limited treatment options. People researching this compound notice the emphasis on material quality, handling standards, and regulatory detail. Knowledge about Olaparib’s physical and chemical traits isn't just scientific curiosity—it helps guide procurement, usage, and safety protocols in hospital and laboratory settings.
Olaparib's molecular formula reads C24H23FN4O3, and this tells you right away that its backbone includes carbon, hydrogen, fluorine, nitrogen, and oxygen atoms. Structural studies reveal a distinctive arrangement: a fused bicyclic core with side chains that confer biological activity. The molecule’s calculated molecular weight sits at approximately 434.47 g/mol, making it a mid-sized organic compound. In laboratory and industrial usage, such specifics guide the preparation of solutions and dosing regimens, preventing costly errors. The molecule’s crystalline structure and purity play a direct role in the consistency of research and clinical outcomes.
Olaparib often comes as a white or off-white crystalline powder, easy to recognize and handle in a clinical or laboratory workspace. Its purity and stability are critical. The density of Olaparib hovers near 1.36 g/cm³ at room temperature, contributing to its solid state under standard conditions. Despite being classified as a powder, Olaparib can appear as fine flakes or granules, depending on the milling process and storage—factors that influence solubility, dosing precision, and ease of preparation. Sometimes, Olaparib is dissolved into solution for ease of application, requiring careful measurement to avoid degradation caused by light or moisture.
Chemically, Olaparib belongs to the family of fused bicyclic heterocycles, which accounts for its stability and reactivity. It resists breakdown under moderate temperature and neutral pH, but strong acids or bases degrade the active structure. Solubility stands at less than 0.1 mg/mL in water, driving the need for specialized solvents—often DMSO or ethanol—in laboratory settings. These material properties affect how pharmaceuticals develop oral, intravenous, or other formulations for patients. Professionals must monitor for polymorphic variation, since crystal structure can shift during transport or under stress, affecting the drug’s bioavailability. Attention to these invisible details ensures patients receive consistent, reliable treatment.
Globally, tracking and transporting Olaparib depends on precise identification under the Harmonized System Code, typically classified as 2933.99 for heterocyclic compounds. Customs officials, logistics staff, and importers refer to this code when declaring shipments, paying duties, and checking compliance. This layer of detail protects patent interests, meets international trade obligations, and prevents delays at borders—a process well understood by researchers familiar with supply chain issues in pharmaceuticals.
Like most targeted therapies, Olaparib poses health and environmental risks when handled improperly. Direct contact with skin, eyes, or inhalation may cause mild irritation, and chronic exposure carries unknown risks for lab staff. Proper ventilation, gloves, and lab coats prove essential in settings where raw materials or prepared solutions are being measured and transferred. Emergency eye-wash and first-aid plans reduce the risk of accidental injury. Waste disposal adheres to chemical regulations, treating Olaparib as potentially hazardous to aquatic life and ensuring no contamination of public water systems. Workplace safety guidelines emphasize locality-specific regulations in handling, labeling, and shipping. People engaged in manufacturing or compounding trust these rigorous steps to keep their workplace safe and productive.
Source material selection for Olaparib manufacture influences everything from purity and stability to overall cost. Pharmaceutical companies rely on established vendors who validate every batch’s certificate of analysis—the margin for error leaves no room for improvisation. Downstream industries, from compounding pharmacies to clinical research labs, benefit from these strict quality checks. Failure to secure reliable raw materials leads to failed batches, regulatory penalties, or dangerous clinical outcomes. People with experience ordering APIs know the hassle of rejected shipments and the real-world urgency behind every successful delivery.
Expanding Olaparib’s availability requires more transparency in sourcing, consistent updates on physical, material, and chemical changes from vendors, and further investment in logistics safety. Improved education about handling, disposal, and documentation mitigates safety hazards, especially in settings new to PARP inhibitors. Adoption of automated analytical methods detects impurity or polymorphism before it enters the care stream. Continuous dialogue among manufacturers, regulatory agencies, clinicians, and laboratory staff helps keep standards high. Future breakthroughs depend on honest assessment and real-time sharing of know-how—strengthening the chain from raw material to finished cure.
